BioCryst Begins Enrollment in Phase 1 Trial Evaluating Bcx17725, a Klk5 Inhibitor, for the Treatment of Netherton Syndrome
BioCryst已開始招募參與者進行第1階段試驗,評估Bcx17725,一種Klk5抑制劑,用於治療Netherton綜合徵
BioCryst Begins Enrollment in Phase 1 Trial Evaluating Bcx17725, a Klk5 Inhibitor, for the Treatment of Netherton Syndrome
BioCryst已開始招募參與者進行第1階段試驗,評估Bcx17725,一種Klk5抑制劑,用於治療Netherton綜合徵
譯文內容由第三人軟體翻譯。